Research advances in abnormal gluconeogenesis in hepatocellular carcinoma

Saifang LUO; Xiangming MA; Liying CAO

doi:10.3969/j.issn.1001-5256.2022.09.042

Volume 38 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(9): 2165-2171

PDF( 4065 KB)

Research advances in abnormal gluconeogenesis in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.09.042

Department of Hepatobiliary Surgery, Kailuan General Hospital Affiliated to North China University of Science and Technology, Tangshan, Hebei 063000, China

Research funding:

2020 Medical Science Research Project Plan of Hebei Province (20201285)

More Information

Corresponding author: CAO Liying, caoliying153@126.com(ORCID: 0000-0003-3662-5961)
Received Date: 2022-02-23
Accepted Date: 2022-04-05
Published Date: 2022-09-20

Abstract

Abstract

Tumors still perform glycolysis in the aerobic environment to accelerate the uptake of glucose and produce a large amount of lactic acid in tumor microenvironment, provide biomolecular precursors of nucleotides, lipids, and proteins for tumor cell proliferation, and inhibit the function of immune cells and promote the metastasis of tumor cells in acidic environment. Gluconeogenesis, as the reverse reaction of glycolysis, is inhibited in hepatocellular carcinoma, especially the downregulated expression of the four key rate-limiting enzymes pyruvate carboxylase, phosphoenolpyruvate carboxykinase, fructose-1, 6-diphosphate 1, and glucose-6-phosphatase 4, which promotes the growth and proliferation of hepatocellular carcinoma by promoting aerobic glycolysis and its branched pathways, and meanwhile, it is also associated with the overall survival time and prognosis of patients with hepatocellular carcinoma and is considered an inhibitor for hepatocellular carcinoma. Therefore, this review summarizes the changes and mechanism of action of the key enzymes of gluconeogenesis in the development and progression of hepatocellular carcinoma and analyzes the shortcomings and future directions of related research in hepatocellular carcinoma, so as to provide new ideas for the treatment of hepatocellular carcinoma.
- Carcinoma, Hepatocellular,
- Gluconeogenesis,
- Metabolism

FullText(HTML)

References(54)

References

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	VIBERT E, SCHWARTZ M, OLTHOFF KM. Advances in resection and transplantation for hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2): 262-276. DOI: 10.1016/j.jhep.2019.11.017.
[3]	WARBURG O. On the origin of cancer cells[J]. Science, 1956, 123(3191): 309-314. DOI: 10.1126/science.123.3191.309.
[4]	VANDER HEIDEN MG, CANTLEY LC, THOMPSON CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation[J]. Science, 2009, 324(5930): 1029-1033. DOI: 10.1126/science.1160809.
[5]	DEBERARDINIS RJ, LUM JJ, HATZIVASSILIOU G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation[J]. Cell Metab, 2008, 7(1): 11-20. DOI: 10.1016/j.cmet.2007.10.002.
[6]	QIAO WJ, LIU XJ. Research progress on reprogramming of T cell glycometabolism and anti-tumor immunotherapy[J]. Chin J Cancer Biother, 2022, 29(1): 75-79. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202201012.htm 乔万佳, 刘小军. T细胞糖代谢重编程与抗肿瘤免疫治疗的研究进展[J]. 中国肿瘤生物治疗杂志, 2022, 29(1): 75-79. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202201012.htm
[7]	FISCHER K, HOFFMANN P, VOELKL S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells[J]. Blood, 2007, 109(9): 3812-3819. DOI: 10.1182/blood-2006-07-035972.
[8]	FENG J, LI J, WU L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2020, 39(1): 126. DOI: 10.1186/s13046-020-01629-4.
[9]	SMOLLE E, LEKO P, STACHER-PRIEHSE E, et al. Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer[J]. Mol Oncol, 2020, 14(11): 2853-2867. DOI: 10.1002/1878-0261.12780.
[10]	LEITHNER K, TRIEBL A, TRÖTZMVLLER M, et al. The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells[J]. Proc Natl Acad Sci U S A, 2018, 115(24): 6225-6230. DOI: 10.1073/pnas.1719871115.
[11]	VINCENT EE, SERGUSHICHEV A, GRISS T, et al. Mitochondrial phosphoenolpyruvate carboxykinase regulates metabolic adaptation and enables glucose-independent tumor growth[J]. Mol Cell, 2015, 60(2): 195-207. DOI: 10.1016/j.molcel.2015.08.013.
[12]	LU C, REN C, YANG T, et al. Fructose-1, 6-bisphosphatase 1 interacts with NF-κB p65 to regulate breast tumorigenesis via PIM2 induced phosphorylation[J]. Theranostics, 2020, 10(19): 8606-8618. DOI: 10.7150/thno.46861.
[13]	LI K, YING M, FENG D, et al. Fructose-1, 6-bisphosphatase is a novel regulator of Wnt/β-Catenin pathway in breast cancer[J]. Biomed Pharmacother, 2016, 84: 1144-1149. DOI: 10.1016/j.biopha.2016.10.050.
[14]	WANG Z, DONG C. Gluconeogenesis in cancer: Function and regulation of PEPCK, FBPase, and G6Pase[J]. Trends Cancer, 2019, 5(1): 30-45. DOI: 10.1016/j.trecan.2018.11.003.
[15]	WANG B, HSU SH, FRANKEL W, et al. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha[J]. Hepatology, 2012, 56(1): 186-197. DOI: 10.1002/hep.25632.
[16]	ZOU J, ZHU X, XIANG D, et al. LIX1-like protein promotes liver cancer progression via miR-21-3p-mediated inhibition of fructose-1, 6-bisphosphatase[J]. Acta Pharm Sin B, 2021, 11(6): 1578-1591. DOI: 10.1016/j.apsb.2021.02.005.
[17]	LIU MX, JIN L, SUN SJ, et al. Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma[J]. Oncogene, 2018, 37(12): 1637-1653. DOI: 10.1038/s41388-017-0070-6.
[18]	GRASMANN G, SMOLLE E, OLSCHEWSKI H, et al. Gluconeogenesis in cancer cells - Repurposing of a starvation-induced metabolic pathway?[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(1): 24-36. DOI: 10.1016/j.bbcan.2019.05.006.
[19]	HAMMOND KD, BALINSKY D. Activities of key gluconeogenic enzymes and glycogen synthase in rat and human livers, hepatomas, and hepatoma cell cultures[J]. Cancer Res, 1978, 38(5): 1317-1322. http://hwmaint.cancerres.aacrjournals.org/cgi/reprint/38/5/1317.pdf
[20]	LEE MH, DEBERARDINIS RJ, WEN X, et al. Active pyruvate dehydrogenase and impaired gluconeogenesis in orthotopic hepatomas of rats[J]. Metabolism, 2019, 101: 153993. DOI: 10.1016/j.metabol.2019.153993.
[21]	HIRATA H, SUGIMACHI K, KOMATSU H, et al. Decreased expression of fructose-1, 6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma[J]. Cancer Res, 2016, 76(11): 3265-3276. DOI: 10.1158/0008-5472.CAN-15-2601.
[22]	CHENG L, HU S, MA J, et al. Long noncoding RNA RP11-241J12.3 targeting pyruvate carboxylase promotes hepatocellular carcinoma aggressiveness by disrupting pyruvate metabolism and the DNA mismatch repair system[J]. Mol Biomed, 2022, 3(1): 4. DOI: 10.1186/s43556-021-00065-w.
[23]	XU D, WANG Z, XIA Y, et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis[J]. Nature, 2020, 580(7804): 530-535. DOI: 10.1038/s41586-020-2183-2.
[24]	PAN XM. The gluconeogenic enzyme FBP1 and PCK1 inhibit HCC tumorigenesis[D]. Chongqing: ChongQing Medical University, 2020. 潘璇明. 糖异生关键酶FBP1和PCK1调控肝细胞癌发生的实验研究[D]. 重庆: 重庆医科大学, 2020.
[25]	GAO Y, WANG X, SANG Z, et al. Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues[J]. Sci Rep, 2017, 7: 45913. DOI: 10.1038/srep45913.
[26]	TUO L, XIANG J, PAN X, et al. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis[J]. J Exp Clin Cancer Res, 2019, 38(1): 50. DOI: 10.1186/s13046-019-1029-y.
[27]	CAI Z, CHEHAB NH, PAVLETICH NP. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase[J]. Mol Cell, 2009, 35(6): 818-829. DOI: 10.1016/j.molcel.2009.09.007.
[28]	CARLONI V, LULLI M, MADIAI S, et al. CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression[J]. Gut, 2018, 67(2): 348-361. DOI: 10.1136/gutjnl-2016-313114.
[29]	XIANG J, CHEN C, LIU R, et al. Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation[J]. J Clin Invest, 2021, 131(8): e144703. DOI: 10.1172/JCI144703.
[30]	ZHANG P, TU B, WANG H, et al. Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion[J]. Proc Natl Acad Sci U S A, 2014, 111(29): 10684-10689. DOI: 10.1073/pnas.1411026111.
[31]	KHAN MW, BISWAS D, GHOSH M, et al. mTORC2 controls cancer cell survival by modulating gluconeogenesis[J]. Cell Death Discov, 2015, 1: 15016. DOI: 10.1038/cddiscovery.2015.16.
[32]	SHI H, FANG R, LI Y, et al. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells[J]. Cancer Lett, 2016, 382(2): 147-156. DOI: 10.1016/j.canlet.2016.08.025.
[33]	LATORRE-MURO P, BAEZA J, ARMSTRONG EA, et al. Dynamic acetylation of phosphoenolpyruvate carboxykinase toggles enzyme activity between gluconeogenic and anaplerotic reactions[J]. Mol Cell, 2018, 71(5): 718-732. DOI: 10.1016/j.molcel.2018.07.031.
[34]	LI M, LUO RZ, CHEN JW, et al. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma[J]. J Transl Med, 2011, 9: 5. DOI: 10.1186/1479-5876-9-5.
[35]	TOMASI ML, TOMASI I, RAMANI K, et al. S-adenosyl methionine regulates ubiquitin-conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers[J]. Hepatology, 2012, 56(3): 982-993. DOI: 10.1002/hep.25701.
[36]	YOKOMIZO C, YAMAGUCHI K, ITOH Y, et al. High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells[J]. Cancer Lett, 2011, 310(2): 140-147. DOI: 10.1016/j.canlet.2011.06.030.
[37]	BIAN XL, CHEN HZ, YANG PB, et al. Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation[J]. Nat Commun, 2017, 8: 14420. DOI: 10.1038/ncomms14420.
[38]	JING Z, GAO J, LI J, et al. Acetylation-induced PCK isoenzyme transition promotes metabolic adaption of liver cancer to systemic therapy[J]. Cancer Lett, 2021, 519: 46-62. DOI: 10.1016/j.canlet.2021.06.016.
[39]	DZUGAJ A. Localization and regulation of muscle fructose-1, 6-bisphosphatase, the key enzyme of glyconeogenesis[J]. Adv Enzyme Regul, 2006, 46: 51-71. DOI: 10.1016/j.advenzreg.2006.01.021.
[40]	YANG J, WANG C, ZHAO F, et al. Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect[J]. Carcinogenesis, 2017, 38(2): 134-143. DOI: 10.1093/carcin/bgw109.
[41]	LI F, HUANGYANG P, BURROWS M, et al. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome[J]. Nat Cell Biol, 2020, 22(6): 728-739. DOI: 10.1038/s41556-020-0511-2.
[42]	LIU GM, LI Q, ZHANG PF, et al. Restoration of FBP1 suppressed snail-induced epithelial to mesenchymal transition in hepatocellular carcinoma[J]. Cell Death Dis, 2018, 9(11): 1132. DOI: 10.1038/s41419-018-1165-x.
[43]	YANG J, JIN X, YAN Y, et al. Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression[J]. Sci Rep, 2017, 7: 43864. DOI: 10.1038/srep43864.
[44]	PAN D, MAO C, WANG YX. Suppression of gluconeogenic gene expression by LSD1-mediated histone demethylation[J]. PLoS One, 2013, 8(6): e66294. DOI: 10.1371/journal.pone.0066294.
[45]	LEITHNER K. Epigenetic marks repressing gluconeogenesis in liver and kidney cancer[J]. Cancer Res, 2020, 80(4): 657-658. DOI: 10.1158/0008-5472.CAN-19-3953.
[46]	LIAO K, DENG S, XU L, et al. A feedback circuitry between polycomb signaling and fructose-1, 6-bisphosphatase enables hepatic and renal tumorigenesis[J]. Cancer Res, 2020, 80(4): 675-688. DOI: 10.1158/0008-5472.CAN-19-2060.
[47]	WATTANAVANITCHAKORN S, ROJVIRAT P, CHAVALIT T, et al. CCAAT-enhancer binding protein-α (C/EBPα) and hepatocyte nuclear factor 4α (HNF4α) regulate expression of the human fructose-1, 6-bisphosphatase 1 (FBP1) gene in human hepatocellular carcinoma HepG2 cells[J]. PLoS One, 2018, 13(3): e0194252. DOI: 10.1371/journal.pone.0194252.
[48]	YANG LN, NING ZY, WANG L, et al. HSF2 regulates aerobic glycolysis by suppression of FBP1 in hepatocellular carcinoma[J]. Am J Cancer Res, 2019, 9(8): 1607-1621. http://www.ncbi.nlm.nih.gov/pubmed/31497345/
[49]	JIN X, PAN Y, WANG L, et al. MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation[J]. Oncogenesis, 2017, 6(4): e312. DOI: 10.1038/oncsis.2017.21.
[50]	RAMADOSS P, UNGER-SMITH NE, LAM FS, et al. STAT3 targets the regulatory regions of gluconeogenic genes in vivo[J]. Mol Endocrinol, 2009, 23(6): 827-837. DOI: 10.1210/me.2008-0264.
[51]	LIANG J, LIU C, QIAO A, et al. MicroRNA-29a-c decrease fasting blood glucose levels by negatively regulating hepatic gluconeogenesis[J]. J Hepatol, 2013, 58(3): 535-542. DOI: 10.1016/j.jhep.2012.10.024.
[52]	PICCININ E, VILLANI G, MOSCHETTA A. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(3): 160-174. DOI: 10.1038/s41575-018-0089-3.
[53]	MA R, ZHANG W, TANG K, et al. Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma[J]. Nat Commun, 2013, 4: 2508. DOI: 10.1038/ncomms3508.
[54]	SHANG F, LIU M, LI B, et al. The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells[J]. Cancer Chemother Pharmacol, 2016, 77(5): 1087-1096. DOI: 10.1007/s00280-016-3030-x.

Relative Articles

[1]	Xiaoli LIU, Qinwen TAN, Jian XU, Huanling CHEN, Jie YU, Lu LU, Mingkan DAI, Jingjing HUANG, Hongna HUANG, Dewen MAO. Effect of amino acid metabolic reprogramming on immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2531-2537. doi: 10.12449/JCH241226
[2]	Huiji SU, Gengjie YAN, Hanxiao CHEN, Shaoqun BAN, Ailing WEI, Dewen MAO, Fuli LONG. Role of macrophage polarization and its crosstalk with neighboring cells in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(5): 1204-1211. doi: 10.3969/j.issn.1001-5256.2023.05.032
[3]	Renjie LU, Fangfang SUN, Jie DU, Lirong ZHAO. Hepatocellular carcinoma with bile duct tumor thrombus: A case report[J]. Journal of Clinical Hepatology, 2022, 38(8): 1872-1874. doi: 10.3969/j.issn.1001-5256.2022.08.028
[4]	Yi CHEN, Li XIE, Jian WU. Role of KRAS mutation in metabolism of pancreatic ductal adenocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(12): 2901-2907. doi: 10.3969/j.issn.1001-5256.2022.12.043
[5]	Tianle GONG, Ping YUE, Jun YAN, Xun LI. Adjuvant therapies after surgery for hepatocellular carcinoma with microvascular invasion[J]. Journal of Clinical Hepatology, 2021, 37(3): 685-688. doi: 10.3969/j.issn.1001-5256.2021.03.037
[6]	Guoxiang CHEN, Mo ZHOU, Sheng CHEN, Yuan WANG, Yuanlong ZHOU, Jihong YANG. Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(3): 699-703. doi: 10.3969/j.issn.1001-5256.2021.03.040
[7]	Shisi LI, Zhitang GUO, Zhangbin CHEN, Yishan TENG. Research advances in systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(12): 2943-2946. doi: 10.3969/j.issn.1001-5256.2021.12.044
[8]	Xu YANG, Zhengrong SHI. Hepatocellular carcinoma with gastrointestinal stromal tumor: A case report[J]. Journal of Clinical Hepatology, 2021, 37(8): 1909-1910. doi: 10.3969/j.issn.1001-5256.2021.08.033
[9]	Huijun XIE, Nasot Rashed, Yong NING, Chuan GAO. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 448-451. doi: 10.3969/j.issn.1001-5256.2021.02.042
[10]	Xin CAI, Juanjuan CHEN, Dongling TANG, Pingan ZHANG. Role of circular RNA in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(3): 695-698. doi: 10.3969/j.issn.1001-5256.2021.03.039
[11]	Xichen LIU, Yiying WANG, Manman TONG, Junjie QIN. Biomarkers for the early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(1): 176-179. doi: 10.3969/j.issn.1001-5256.2021.01.038
[12]	Yong ZHANG, Zhengfa MAO. Association of tuberous sclerosis gene 1/2 mutations with the progression of hepatocellular carcinoma and prognosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 84-88. doi: 10.3969/j.issn.1001-5256.2021.01.017
[13]	Zherui LIU, Xiaodong JIA, Yinying LU. Research advances in hepatocellular carcinoma-related imbalance of bile acid metabolism and related regulatory mechanism[J]. Journal of Clinical Hepatology, 2021, 37(3): 690-694. doi: 10.3969/j.issn.1001-5256.2021.03.038
[14]	Yang YANG, Yinan DENG. Application of immunosuppressants after liver transplantation for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 263-266. doi: 10.3969/j.issn.1001-5256.2021.02.005
[15]	Ri LI, Huaibin GUO, Ze LIANG, Na LI, Junye WEN, Wanxing ZHANG. Primary hepatic carcinosarcoma with hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2021, 37(9): 2180-2182. doi: 10.3969/j.issn.1001-5256.2021.09.034
[16]	Pingfu XIONG, Hao CHEN, Wenguang FU, Peng TAN, Yonglang CHENG, Jing LI. Research advances in Kupffer cells participating in the regulation of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(10): 2448-2451. doi: 10.3969/j.issn.1001-5256.2021.10.040
[17]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[18]	Ningning ZHANG, Wei LU. Targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1753-1757. doi: 10.3969/j.issn.1001-5256.2021.08.003
[19]	Luo Yan, Shi JunPing. Research advances in the pathogenesis of nonalcoholic fatty liver disease-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1217-1220. doi: 10.3969/j.issn.1001-5256.2020.06.005
[20]	Wu Jing, Meng QingHua, Xue Ran. Effect of tumor-stroma crosstalk on amino acid metabolism in hepatic stellate cells[J]. Journal of Clinical Hepatology, 2018, 34(12): 2610-2613. doi: 10.3969/j.issn.1001-5256.2018.12.020

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	安明宇，杨霞，程方玲，杨凯平，朱燚，张楠楠，李军. 葛根素调控铁死亡干预肝细胞癌的机制研究. 贵州科学. 2024(02): 46-52 .
2.	陈爽，李红. 沉默FOXK1基因对胃癌HGC-27细胞增殖、迁移和侵袭的影响. 吉林大学学报(医学版). 2024(02): 371-378 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3)

Get Citation

PDF

XML

Article Metrics

Article views (788) PDF downloads(78)

Research advances in abnormal gluconeogenesis in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.09.042